Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;5(3):214-223.
doi: 10.1016/S2213-8587(16)00034-6. Epub 2016 Feb 23.

Male hormonal contraception: hope and promise

Affiliations
Review

Male hormonal contraception: hope and promise

Katarzyna Piotrowska et al. Lancet Diabetes Endocrinol. 2017 Mar.

Abstract

Family planning is a shared responsibility, but available male-directed contraceptive methods are either not easily reversible (vasectomy) or not sufficiently effective (condom). However, roughly 20% of couples using a contraceptive method worldwide, and up to 80% in some countries, still choose a male-directed method. Male hormonal contraception is highly effective, with perfect use failure rates of 0·6% (95% CI 0·3-1·1) if sperm concentrations of less than 1 million per mL are maintained. After cessation of male hormonal contraception, sperm output fully recovers in a predictable manner, resulting in pregnancies and livebirths. Spontaneous miscarriage and fetal malformation rates after recovery of sperm output overlap those in the general population. Short-term adverse events-acne, night sweats, increased weight, and altered mood and libido-are recognised, but are generally mild. Further optimisation of specific androgen-progestin regimens and phase 3 studies of lead combinations are still needed to successfully develop an approved male hormonal contraceptive and to identify long-term side-effects.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests

KP and PYL declare no conflicts of interests. CW received research support from Clarus Therapeutics, Lipocine, Prolor and Besins Healthcare International and is a consultant for Lipocine and TesoRX. RSS received research support from AbbVie and Clarus Therapeutics, Lipocine, Prolor and Besins Healthcare International and is a consultant for Anatres, Clarus Therapeutics, Lipocine and Novartis.

References

    1. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C Hormonal Male Contraception Summit Group. Rate, extent and modifiers of spermatogenic recovery after hormonal male contraception: An integrated analysis. Lancet. 2006;367(9520):1412–20. - PubMed
    1. Peterson HB, Darmstadt GL, Bongaarts J. Meeting the unmet need for family planning: now is the time. Lancet. 2013;381(9879):1696–9. - PubMed
    1. Page ST, Amory JK, Bremner WJ. Advances in male contraception. Endocr Rev. 2008;29(4):465–93. - PMC - PubMed
    1. Chao J, Page ST, Anderson RA. Male contraception. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):845–57. - PMC - PubMed
    1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–6. - PMC - PubMed

Publication types